Novel Device Measures Glucose in Urine
|
By LabMedica International staff writers Posted on 01 Dec 2015 |
|
Image: The GlucosAlarm device in the toilet can measure blood glucose levels through the urine and is activated through a smart phone application (Photo courtesy of Chihuahua Institute of Technology).
A device has been developed that can measure glucose in blood through the urine in the toilet, and it activates via smart phone bluetooth, recording the values on a daily basis.
One of the values taken into account for the design was the pain caused by the use of needles for monitoring glucose in blood, which is partly responsible of why patients with diabetes do not keep proper control of their disease.
Two young technologists at the Chihuahua Institute of Technology (Mexico) developed the device which has achieved international recognition, included being one of the 10 most outstanding creations among innovators under 35 delivered by the MIT Tech Review; it also won the Global Innovation Competition for Science and Technology for the Benefit of Mankind (GIST Tech-I), an initiative promoted by the US President, where the team competed against 900 technological developments from all over the world.
The device is called the Glucosalarm (Brownsville, TX, USA) and it uses two 70 mL bottles, one contains an enzyme and the other one contains a cleaning solution, which last for 140 measurements and are easily replaceable. The device uses a light sensor that detects the frequency of glucose in urine and measures it in 15 to 40 seconds. Only one drop of urine is needed and this can be done when the patient uses the toilet and there is no need for painful blood testing. Another reason for not having a constant monitoring is the cost. A glucometer costs less than USD 30, but the test strips are expensive, as well as needles and needle holders, which is money that is not available to everyone. Glucosalarm will cost approximately USD 120 to USD 140 and the readings will cost less than a penny per measurement.
Currently, the device is in the third prototype and tests are performed with patients. It also has a patent in Mexico and the United States, and two medical device companies with international presence have shown interest in manufacturing it. Glucosalarm is expected to be released in the USA and Mexico in late 2016 and early 2017, once the necessary authorizations are obtained from the US Food and Drug Administration (FDA, Silver Springs, MD, USA) and the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS; Benito Juárez, Mexico).
Related Links:
Chihuahua Institute of Technology
GlucosAlarm
US Food and Drug Administration
One of the values taken into account for the design was the pain caused by the use of needles for monitoring glucose in blood, which is partly responsible of why patients with diabetes do not keep proper control of their disease.
Two young technologists at the Chihuahua Institute of Technology (Mexico) developed the device which has achieved international recognition, included being one of the 10 most outstanding creations among innovators under 35 delivered by the MIT Tech Review; it also won the Global Innovation Competition for Science and Technology for the Benefit of Mankind (GIST Tech-I), an initiative promoted by the US President, where the team competed against 900 technological developments from all over the world.
The device is called the Glucosalarm (Brownsville, TX, USA) and it uses two 70 mL bottles, one contains an enzyme and the other one contains a cleaning solution, which last for 140 measurements and are easily replaceable. The device uses a light sensor that detects the frequency of glucose in urine and measures it in 15 to 40 seconds. Only one drop of urine is needed and this can be done when the patient uses the toilet and there is no need for painful blood testing. Another reason for not having a constant monitoring is the cost. A glucometer costs less than USD 30, but the test strips are expensive, as well as needles and needle holders, which is money that is not available to everyone. Glucosalarm will cost approximately USD 120 to USD 140 and the readings will cost less than a penny per measurement.
Currently, the device is in the third prototype and tests are performed with patients. It also has a patent in Mexico and the United States, and two medical device companies with international presence have shown interest in manufacturing it. Glucosalarm is expected to be released in the USA and Mexico in late 2016 and early 2017, once the necessary authorizations are obtained from the US Food and Drug Administration (FDA, Silver Springs, MD, USA) and the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS; Benito Juárez, Mexico).
Related Links:
Chihuahua Institute of Technology
GlucosAlarm
US Food and Drug Administration
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines
Channels
Molecular Diagnostics
view channel
Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
Two studies have identified proteins in the blood that could potentially alert individuals to the presence of cancer more than seven years before the disease is clinically diagnosed. Researchers found... Read more (1)_1.jpg "Image: Ultrasound image of micro-histotripsy liberation of biomarkers in a tumor (Photo courtesy of Joy Wang and Pradyumna Kedarisetti)"){kind=small}
Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
Ultrasound imaging serves as a noninvasive method to locate and monitor cancerous tumors effectively. However, crucial details about the cancer, such as the specific types of cells and genetic mutations... Read more_1.jpg "Image: The innovative method to customize and strengthen DNA origami structure promises breakthroughs in medicine (Photo courtesy of Shutterstock)")
.jpg "Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)")
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. Traditional intraoperative assessments, such as frozen sections based on H&E... Read more
HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
Annually, over 604,000 women across the world are diagnosed with cervical cancer, and about 342,000 die from this disease, which is preventable and primarily caused by the Human Papillomavirus (HPV).... Read more
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read more
Technology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
